UMIN-CTR Clinical Trial

Recruitment status Enrolling by invitation
Unique ID issued by UMIN UMIN000024530
Receipt No. R000028235
Scientific Title Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study
Date of disclosure of the study information 2017/04/01
Last modified on 2019/05/08 (Ver. 14)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study
Acronym NExT-DN
Scientific Title Identification of New Biomarkers to Explore Pathology of Renal Tissue and to Predict Outcomes of Diabetic Nephropathy Study
Scientific Title:Acronym NExT-DN
Region
Japan

Condition
Condition Diabetes
Diabetic nephropathy
Classification by specialty
Endocrinology and Metabolism Nephrology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate new prognostic and diagnostic indicators of diabetic nephropathy
Basic objectives2 Others
Basic objectives -Others To explore the new therapeutic target of diabetic nephropathy
Trial characteristics_1
Trial characteristics_2 Others
Developmental phase

Assessment
Primary outcomes eGFR 30-40% decline from baseline
Key secondary outcomes 1. Investigation of clinicopathologic indocators of renal progression in diabetic nephropathy
I. eGFR decline > 3-5 ml/min/1.73m2/year
II. Commencement of dialysis or renal transplantation because of end stage renal disease
III. Development of albuminuric stage

2. Investigation of other major complications of diabetes
I.Development of diabetic retinopathy
II.CVD event
III.Death

3. Exploration of new biomarkers to predict diabetic nephropathy in patients with diabetes.
I. Diabetic nephrpathy vs no renal disease
II. Diabetic nephropathy vs other renal diseases
* Investigation of biomarmers to differenciate I and II

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Diagnosis
Type of intervention
Maneuver
Interventions/Control_1 To evaluate renal disease in patients with diabetes by renal biopsy
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria 1. Patients who go to our department from the time after approval of this study by the ethics committee of our hospital to March 31th, 2024.
2. Patients who agreee IC
3. Patients whose age is no less than 20 and no more than 80 at the time of IC.
Key exclusion criteria 1. Patients with diabetes due to other reasons except for type 1 and 2 diabetes, such as steroid-induced diabetes, Cushing syndrome, and genetic diabetes
2. Female in pregnancy or with possibility of pregnancy
3. Patients with high risk of renal biopsy
High risk is defined as any one of the following 6 criteria.
i. Platelet count < 100,000 (/ul) or definite disordered coagulation
ii. Usage of antiplatelet drug and anticoagulated drug which can not be stopped temporarily.
iii. Progressive anemia except for renal anemia
iv. Patients who can not keep a position in bed during renal biopsy.
v. Morphologic problems revealed by image information
Specifically, multiple cysts on the puncture line, renal cortex thickness < 10mm, and so on.
vi. Patients whom primary physician clinically defined as patients at high risk because of other reasons.
4. Patients under the emergency situations, such as life-threatening and infectious situation.
5. Baseline eGFR < 15ml/min/1.73m2
Target sample size 200

Research contact person
Last name of lead principal investigator
1st name Jun
Middle name
Last name Wada
Organization Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Division name Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Zip code 700-8558
Address 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
TEL 81-86-235-7235
Email junwada@okayama-u.ac.jp

Public contact
1st name of contact person
1st name Koki
Middle name
Last name Mise
Organization Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Division name Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Zip code 700-8558
Address 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
TEL 81-86-235-7235
Homepage URL
Email kokims-frz@okayama-u.ac.jp

Sponsor
Institute Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Institute
Department

Funding Source
Organization Nothing
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Center for Innovative Clinical Medicine, Ethics Committee
Address 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan
Tel 086-235-6503
Email mae6605@adm.okayama-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions Okayama university hospital

Other administrative information
Date of disclosure of the study information
2017 Year 04 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Enrolling by invitation
Date of protocol fixation
2016 Year 12 Month 26 Day
Date of IRB
2017 Year 02 Month 21 Day
Anticipated trial start date
2017 Year 03 Month 31 Day
Last follow-up date
2027 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 10 Month 23 Day
Last modified on
2019 Year 05 Month 08 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000028235